Sensex, Nifty end at new all-time high for third day amid vaccine optimism

The Sensex rose 347 points, or 0.77 per cent, to end at 45,427, while the Nifty gained 97 points, or 0.73 per cent, to close at 13,356

BSE, markets
People walk past the Bombay Stock Exchange (BSE) building in Mumbai. Photo: Reuters
Sundar Sethuraman Thiruvananthapuram
2 min read Last Updated : Dec 07 2020 | 11:52 PM IST
The benchmark indices advanced for the fifth straight day on Monday, led by gains in consumer goods and banking stocks amid optimism around the progress in Covid vaccines. Both Sensex and Nifty ended at a new all-time high for the third day. The Sensex rose 347 points, or 0.77 per cent, to end at 45,427, while the Nifty gained 97 points, or 0.73 per cent, to close at 13,356. HDFC, Hindustan Unilever, ICICI Bank and ITC made bigger contributions to index gains. HDFC Bank and Kotak Mahindra Bank were the biggest drags.

“We expect the domestic market to remain strong, backed by vaccine progress, economic recovery and strong FII inflows. However, investors should consider partial profit-booking in pockets trading very expensive, like highly valued large-caps, and trade vigilantly in small- and micro-caps, though the momentum is expected to remain positive in the short- to medium-term,” said Vinod Nair, head of research, Geojit Financial Services.


The benchmark indices have rallied 15 per cent since November 1. The sharp run-up in the market has been underpinned by the record pace of foreign portfolio inflows (FPIs). India’s latest market capitalisation is Rs 181 trillion, or nearly $2.5 trillion.

Experts said the news flow around vaccine progress is helping keep investor sentiment buoyant. The Serum Institute of India, the world’s largest producer of vaccines by volume, has made the formal application for emergency use approval for AstraZeneca Covid-19 vaccine. Also, India’s daily Covid count has remained below 50,000 for a month. With Agency inputs

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Markets Sensex NiftyCoronavirus Vaccinestock marketMarket rally

Next Story